Journal of Osteoporosis

Purinergic Signaling in Bone

Publishing date
07 Sep 2012
Submission deadline
02 Mar 2012

1Research Center for Ageing and Osteoporosis, Departments of Clinical Biochemistry and Medicine, Copenhagen University Hospital Glostrup, 2600 Glostrup, Denmark

2Section of General Pathology, Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy

3Bone Biology Laboratory, Department of Cell and Developmental Biology, University College London, London, UK

4Research Center for Ageing and Osteoporosis, Departments of Medicine and Clinical Biochemistry, Copenhagen University Hospital Glostrup, 2600 Glostrup, Denmark; Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark

Purinergic Signaling in Bone


P2 purinergic signaling in bone is an emerging field and, over the last few decades, has proved to be an important system in the regulation of bone metabolism. Moreover, recent studies have shown that P2 purinergic signaling is not only involved in the regulation of bone cell function in vitro, but in vivo studies have confirmed the importance of the system in bone physiology. These studies have also demonstrated that it might be a potential target in the treatment of bone metabolic disease. Finally, genetic variation on P2 purinergic receptors has been shown to be associated with postmenopausal osteoporosis and the risk of vertebral thereby possibly playing a role in osteoporosis etiology and pathogenesis. However, as the field is still emerging, many other aspects of purinergic signaling in bone are still unexplored.

We invite authors to submit original research and review articles that seek to elucidate the role of the P2 purinergic system in bone from a broad perspective including roles in normal bone modeling and remodeling, in bone metabolic diseases like osteoporosis, in cancers that affect bone (primary bone cancers, metastasis, multiple myeloma, etc), in the interaction between bone and other systems such as the nervous system and the immune system, and in pain. Basic, translational, clinical, and epidemiological studies are welcome. Potential topics include, but are not limited to:

  • The role of purinergic receptors in bone cell function, matrix formation, and mineralization
  • ATP release mechanisms in bone
  • Regulation of nucleotide degradation
  • Genetic variations in purinergic signaling and association to bone diseases
  • The involvement of P2 receptors in autoimmune diseases and autoimmune-mediated bone loss
  • Pain and purinergic receptors
  • Purinergic signaling and cancer/metastasis in bone
  • The purinergic system as a pharmacologic target in bone
  • P2 purinergic signaling in mechanotransduction in bone
  • Purinergic signaling in animal models of bone diseases
  • Interaction between the purinergic signaling system, hormones, and growth factors in bone
  • The purinergic signaling system on the border between immune system, the nervous system, and the skeleton

Before submission authors should carefully read over the journal's Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Journal of Osteoporosis
 Journal metrics
Acceptance rate17%
Submission to final decision79 days
Acceptance to publication19 days
Impact Factor-

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.